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Volume 6Available online XXXBackground: There is no clear consensus on the recommended second-line treatment for patients with metastatic
pancreatic cancer who have disease progression following gemcitabine-based therapy. We retrospectively evaluated
the clinical outcomes of liposomal irinotecan (nal-IRI) plus fluorouracil/leucovorin (FL) and FOLFIRINOX (fluorouracil,
leucovorin, irinotecan, and oxaliplatin) in patients who had failed on the first-line gemcitabine-based therapy.
Patients and methods: From January 2015 to August 2019, 378 patients with MPC who had received nal-IRI/FL
(n ¼ 104) or FOLFIRINOX (n ¼ 274) as second-line treatment across 11 institutions were included in this
retrospective study.
Results: There were no significant differences in baseline characteristics between groups, except age and first-line
regimens. With a median follow-up of 6 months, the median progression-free survival (PFS) was 3.7 months with
nal-IRI/FL versus 4.6 months with FOLFIRINOX (P ¼ 0.44). Median overall survival (OS) was 7.7 months with nal-IRI/
FL versus 9.7 months with FOLFRINOX (P ¼ 0.13). There was no significant difference in PFS and OS between the
two regimens in the univariate and multivariate analyses. The subgroup analysis revealed that younger age (<70
years) was associated with better OS with FOLFIRINOX. In contrast, older age (70 years) was associated with
better survival outcomes with nal-IRI/FL. Adverse events were manageable with both regimens; however, the
incidence of grade 3 or higher neutropenia and peripheral neuropathy was higher in patients treated with
FOLFIRINOX than with nal-IRI/FL.
Conclusions: Second-line nal-IRI/FL and FOLFIRINOX showed similar effectiveness outcomes after progression following
first-line gemcitabine-based therapy. Age could be the determining factor for choosing the appropriate second-line
therapy.
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Despite recent advances in diagnostic technology and anti-
cancer drugs, pancreatic cancer continues to have a poor
prognosis worldwide. It is the fourth leading cause of
cancer-related death in the United States1 and the fifth
leading cause of cancer-related death in South Korea.2
Approximately 80%-90% of patients with pancreatic can-
cer are diagnosed at an advanced stage and overall the
5-year survival rate is only 3%.1,2https://doi.org/10.1016/j.esmoop.2021.100049 1
ESMO Open H. S. Park et al.The MPACT study has reported that a first-line therapy of
albumin-bounded paclitaxel (nab-paclitaxel) with gemcita-
bine significantly improve the survival of patients
with metastatic pancreatic cancer compared with gemcita-
bine monotherapy.3 Gemcitabine monotherapy remains
a valid treatment option for patients with poor
performance status.4 Previous studies have assessed the
role of 5-fluorouracil (5-FU)-based therapies in patients who
progressed following gemcitabine-based therapy5-9; how-
ever, there is no clear consensus on the best second-line
treatment for patients with metastatic pancreatic cancer
(MPC) after progression following gemcitabine-based
chemotherapy.
The randomized, phase III NAPOLI-1 study has revealed
that liposomal irinotecan (nal-IRI) plus fluorouracil/leuco-
vorin (FL) has shown significant survival benefit when
compared with FL monotherapy in patients with MPC who
had been previously treated with gemcitabine-based ther-
apy.10 FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and
oxaliplatin), one of the standard first-line chemotherapy
regimens for patients with MPC,11 shows clinically accept-
able outcomes as the second-line treatment after progres-
sion following gemcitabine-based chemotherapy; however,
no randomized trial data have been published.12-14 Both
nal-IRI/FL and FOLFIRINOX are effective combination
second-line chemotherapies for medically fit patients;
however, no prospective or retrospective comparative study
of these regimens has been undertaken.
In this study, we carried out a multicenter retrospective
analysis to compare the efficacy and safety profiles of nal-
IRI/FL and FOLFIRINOX as the second-line treatment for
patients with MPC after progression following gemcitabine-
based therapy.PATIENTS AND METHODS
Patients
This retrospective, multicenter (11 tertiary referral centers)
study was conducted by the hepatobiliary and pancreatic
cancer division of the Korean Cancer Study Group (KCSG).
Patients with histologically or cytologically confirmed MPC
who received either nal-IRI/FL or FOLFIRINOX as the
second-line treatment after progression on first-line gem-
citabine-based therapy between January 2015 and August
2019 were identified and their medical records were
reviewed. Patients who had recurrence within 6 months
after the completion of adjuvant gemcitabine-based
chemotherapy were regarded as failed on palliative first-
line therapy. This study was approved by the institutional
review board of each institution as required. The require-
ment of informed consent was waived due to the retro-
spective nature of this study.Treatment and assessment
Nal-IRI/FL consisted of intravenous infusion of nal-IRI
70 mg/m2 followed by leucovorin 400 mg/m2 with a2 https://doi.org/10.1016/j.esmoop.2021.100049continuous fluorouracil 2400 mg/m2 every 2 weeks, as
described in the NAPOLI-1 trial.10 FOLFIRINOX consisted of
intravenous infusion of oxaliplatin 85 mg/m2 followed by
irinotecan 180 mg/m2, leucovorin 400 mg/m2, and a bolus
of fluorouracil 400 mg/m2 with a continuous infusion of
fluorouracil 2400 mg/m2 every 2 weeks, as described in the
PRODIGE 4/ACCORD 11 trial.11 Dose modification was
allowed at the discretion of the attending physician in pa-
tient subgroups, such as older age patients or those with a
poor performance status. Treatment was continued until
disease progression or intolerable toxicity. Imaging studies,
including computed tomography or magnetic resonance
imaging, were carried out every 6 or 8 weeks. Adverse
events were monitored at every clinic visit. Tumor response
and adverse events were graded by Response Evaluation
Criteria In Solid Tumor (RECIST) version 1.1 and National
Cancer Institute (NCI)-Common Terminology Criteria for
Adverse Events (CTCAE) version 4.03, respectively.Statistical analysis
Progression-free survival (PFS) was defined as the duration
from treatment initiation to disease progression or any
cause of death, whichever occurred first. Overall survival
(OS) was defined as the duration from treatment initiation
to any cause of death. Pearson’s chi-square and Fisher’s
exact tests were used to compare discrete data. Survival
outcomes were estimated using the KaplaneMeier method
and compared using the log-rank test. Univariate and
multivariate analyses were carried out using the Cox pro-
portional hazard model. A two-sided P value <0.05 was
considered statistically significant. All statistical analyses
were carried out using Statistical Package for the Social
Sciences, version 24.0 for Windows (SPSS Inc., Chicago, IL).RESULTS
Patient characteristics
A total of 378 patients were included in this study who
received nal-IRI/FL (n ¼ 104) or FOLFIRINOX (n ¼ 274).
Patient characteristics are shown in Table 1. All baseline
patient characteristics, except age and prior gemcitabine-
based chemotherapy regimens, were not significantly
different between groups. Median age was higher in pa-
tients treated with nal-IRI/FL than those treated with FOL-
FIRINOX (64 versus 61 years, P ¼ 0.013). The gemcitabine/
nab-paclitaxel combination was used more frequently in
patients treated with nal-IFI/FL than those with FOLFIRINOX
(85.6% versus 51.5%). Gemcitabine monotherapy or an
older gemcitabine-based combination using capecitabine,
erlotinib, or cisplatin were more commonly used in patients
with FOLFIRINOX (48.5% versus 14.4%). There was no dif-
ference in the history of prior surgery between nal-IRI plus
FL and FOLFIRINOX groups (36.5% versus 40.7%, P ¼ 0.464);
however, more patients who had a recurrence within 6
months after the completion of adjuvant gemcitabine
monotherapy or gemcitabine-capecitabine combinationVolume 6 - Issue 2 - 2021






No. % No. %
Age (years)
Median (range) 64 (35-78) 61 (34-81) 0.013
<65 53 51.0 170 62.0 0.05
65 51 49.0 104 38.0
<70 76 73.1 215 78.5 0.266
70 28 26.9 59 21.5
Sex
Male 61 58.7 152 55.5 0.578
Female 43 41.3 122 44.5
ECOG
0-1 86 82.7 223 88.5 0.142
2 18 17.3 29 11.5
Histology
Adenocarcinoma 103 99.0 261 95.3 0.083
Othersa 1 1.0 13 4.7
Location
Head 46 44.2 146 53.7 0.1
Body 26 25.0 46 16.9
Tail 30 28.8 66 24.3
Multicentric 2 2.0 14 5.1
Prior surgery
No 66 63.5 162 59.3 0.464
Yes 38 36.5 111 40.7
Metastatic site
Liver
No 33 31.7 97 35.4 0.502
Yes 71 68.3 177 64.6
Lung
No 81 77.9 217 79.2 0.78
Yes 23 22.1 57 20.8
Peritoneum
No 70 67.3 168 61.3 0.281
Yes 34 32.7 106 38.7
Bone
No 95 91.3 253 92.3 0.751
Yes 9 8.7 21 7.7
Number of metastatic sites
<2 69 66.3 179 65.3 0.852
2 35 33.7 95 34.7
Laboratory values
(median, range)
Albumin (g/dl) 3.7 (1.6-4.7) 3.8 (2.1-4.9) 0.038
NLR (ratio) 2.4 (0.6-14.6) 2.8 (0.4-74.4) 0.537
CA19-9 (U/ml) 292.3 (1.2-91 765) 259 (0-69 938) 0.83
Prior first-line therapy
Gemcitabine monotherapy 6 5.8 67 24.4 <0.001
Gemcitabine/nab-paclitaxel 89 85.6 141 51.5
Gemcitabine/othersb 9 8.6 66 24.1
Subsequent chemotherapy
No 64 61.5 142 51.8 0.227
Yes 35 33.6 118 43.1
Unknown 5 4.8 14 5.1
CA19-9, carbohydrate antigen 19-9; ECOG, European Eastern Oncology Group;
nal-IRI, liposomal irinotecan; NLR, neutrophil-lymphocyte ratio; No, number.
a Intraductal neoplasm with invasive carcinoma, and acinar cell carcinoma.
b Capecitabine, cisplatin, erlotinib, or investigational product.
H. S. Park et al. ESMO Opentherapy were treated with FOLFIRINOX than with nal-IRI/FL
[28.9% (n ¼ 74) versus 10.6% (n ¼ 11), P < 0.001]. Third-
line chemotherapy was administered to 153 patients
(40.5%) following progression after second-line nal-IRI/FL
or FOLFIRINOX; there was no difference between groups
(P ¼ 0.227).Volume 6 - Issue 2 - 2021Effectiveness outcomes
The median follow-up durations for all patients, patients
treated with nal-IRI/FL, and patients treated with FOLFIR-
INOX were 6 (range, 0.2-44.4), 4.9 (range, 0.2-24.5), and 6.2
(range, 0.5-44.4) months, respectively. The effectiveness
outcomes are summarized in Table 2. There was no differ-
ence in median PFS between groups: 3.7 [95% confidence
interval (CI): 2.3-5.1] and 4.6 (95% CI: 3.7-5.5) months for
patients treated with nal-IRI/FL and FOLFIRINOX, respec-
tively (P ¼ 0.444; Figure 1A). Six-month PFS rates were
30.9% and 39.5% in nal-IRI/FL and FOLFIRINOX groups,
respectively. There was no difference in median OS between
groups: 7.7 (95% CI: 5.6-9.8) and 9.7 (95% CI: 8.5-10.9)
months for patients treated with nal-IRI/FL and FOLFIR-
INOX, respectively (P ¼ 0.133; Figure 1B). One-year survival
rates were 26.5% and 39.9% in nal-IRI/FL and FOLFIRINOX
groups, respectively. Objective response rates were 11.5%
and 14.2% with nal-IRI/FL and FOLFIRINOX, respectively
(P ¼ 0.493). The disease control rate was higher in patients
treated with FOLFIRINOX compared with nal-IRI plus FL
(63.1% versus 47.1%, P ¼ 0.005).
The multivariate analysis identified ECOG status (0 or 1
versus 2), liver metastasis, albumin (<3.5 versus 3.5 g/dl),
and CA19-9 (<40 versus 40 U/ml) as independent prog-
nostic factors for PFS (Supplementary Table S1, available at
https://doi.org/10.1016/j.esmoop.2021.100049) while liver
metastasis, peritoneal metastasis, albumin (<3.5 versus
3.5 g/dl), and CA19-9 (<40 versus 0 U/ml) were inde-
pendent prognostic factors for OS (Supplementary Table S2,
available at https://doi.org/10.1016/j.esmoop.2021.100049).
Interestingly, chemotherapy regimen (nal-IRI/FL versus FOL-
FIRINOX) was not retained in the final multivariate models
for PFS and OS.
Subgroup analyses revealed no difference in median PFS
between patients aged <70 years [adjusted hazard ratio
(HR) ¼ 0.85, 95% CI: 0.59-1.22, P ¼ 0.382]; however,
treatment with nal-IRI/FL showed a better PFS than with
FOLFIRINOX in patients aged 70 years (adjusted HR for
PFS ¼ 2.18, 95% CI: 1.09-4.36, P ¼ 0.027; Figure 2A). The
FOLFIRINOX group showed better OS than with the nal-IRI/
FL group in patients aged <70 years [median OS, 9.8
months (95% CI: 8.2-11.4) versus 6.6 months (95% CI: 5.4-
7.9); adjusted HR ¼ 0.60, 95% CI: 0.40-0.88, P ¼ 0.01;
Figure 2B]. In contrast, the nal-IRI/FL group showed better
OS than the FOLFIRINOX group [10.4 (95% CI: 0.0-24.0)
versus 9.5 months (95% CI: 7.3-11.8); adjusted HR ¼ 3.20,
95% CI: 1.28-8.02, P ¼ 0.013].
Safety profiles
Dose modification at first cycle was more commonly done
for patients treated with FOLFIRINOX than those with nal-
IRI/FL (78.5% versus 33.7%). The proportions of patients
with a dose intensity at first cycle 80% of the original dose
were 91.3% and 59.5% in the FOLFIRINOX and nal-IRI/FL
groups, respectively; those with 70% of the original
dose were 100% and 93.4%, respectively.https://doi.org/10.1016/j.esmoop.2021.100049 3








3.7 2.3-5.1 4.6 3.7-5.5 0.444
PFS rate at 6 months,
% (95% CI)
30.9 20.6-41.2 39.5 33.2-45.8
PFS rate at 12 months,
% (95% CI)
21.5 11.6-31.5 10.6 6.0-15.1
OS, months,
median (95% CI)
7.7 5.6-9.8 9.7 8.5-10.9 0.133
OS rate at 6 months,
% (95% CI)
63.1 52.7-73.5 68.6 62.7-74.4
OS rate at 12 months,
% (95% CI)
26.5 14.7-38.3 39.9 32.8-47.0
Objective response rate,
No. (%)
12 11.5 39 14.2 0.493
Disease control rate,
No. (%)




CR 1 1 2 0.7
PR 11 10.6 37 13.5
SD 37 35.6 134 48.9
PD 37 35.6 70 25.5
Not evaluable 18 17.3 31 11.3
CI, confidence intervals; CR, complete response; nal-IRI, liposomal irinotecan; No,
number; OS, overall survival; PFS, progression-free survival; PD, progressive disease;
PR, partial response; SD, stable disease.
ESMO Open H. S. Park et al.The treatment-emergent adverse events of grade 3 or
higher are listed in Table 3. Grade 3-4 neutropenia was re-
ported more often in patients treated with FOLFIRINOX than
in those with nal-IRI/FL (47.2% versus 35%, P ¼ 0.033).
Grade 3-4 peripheral neuropathy was more common in the
FOLFIRINOX group than in the nal-IRI/FL group (5.9% versus
1.0%, P ¼ 0.049). There were no other significant differences
in toxicity profiles. The treatment-emergent adverse events
of all grades are listed in Supplementary Table S3, available
at https://doi.org/10.1016/j.esmoop.2021.100049. Any
grade of neutropenia and thrombocytopenia were more
common in the FOLFIRINOX group than in the nal-IRI/FLFigure 1. KaplaneMeier curves according to chemotherapy regimens.
(A) Progression-free survival, (B) overall survival.
CI, confidence interval; FOLFIRINOX, fluorouracil, leucovorin, irinotecan, and oxaliplat
overall survival; PFS, progression-free survival.
4 https://doi.org/10.1016/j.esmoop.2021.100049group (neutropenia: 65.3% versus 46.6%, P ¼ 0.001;
thrombocytopenia: 17.3% versus 6.8%, P ¼ 0.01). Any grade
of peripheral neuropathy was more frequently observed in
the FOLFIRINOX group than in the nal-IRI/FL group (34.7%
versus 20.4%, P ¼ 0.007).DISCUSSION
This multicenter retrospective study represents that nal-IRI/
FL and FOLFIRINOX showed clinically meaningful effective-
ness as the second-line chemotherapy for patients with
MPC after progression following first-line gemcitabine-
based chemotherapy. Severe neutropenia and peripheral
neuropathy were more common in the FOLFIRINOX group;
however, adverse events were well manageable in both
treatment groups. Interestingly, the subgroup analysis
revealed that FOLFIRINOX was associated with better OS
compared with nal-IRI/FL in patients aged <70 years, while
nal-IRI/FL showed better PFS and OS compared with FOL-
FIRINOX in patients aged 70 years.
Gemcitabine has been used as the standard therapy for
patients with MPC.15 First-line nab-paclitaxel plus gemcita-
bine has shown significant survival benefits when compared
with gemcitabine monotherapy.3 Oxaliplatin-5-FU doublet
combination chemotherapy has shown conflicting results
after progression following first-line gemcitabine therapy
among phase II and III trials5-7; however, NAPOLI-1, inter-
national multicenter phase III trial, has reported that nal-
IRI/FL improves clinical outcomes when compared with FL
in patients with gemcitabine-refractory MPC.10 In the cur-
rent study, patients who were treated with nal-IRI/FL
showed 3.7 months of median PFS and 7.7 months of
median OS, which were in line with the results of the
NAPOLI-1 trial and previous real-world retrospective
studies.10,16-18 Therefore, our study reaffirms the clinical
value of nal-IRI/FL in the management of gemcitabine-
refractory MPC.in; nal-IRI/FL, liposomal irinotecan plus fluorouracil/leucovorin; No, number; OS,
Volume 6 - Issue 2 - 2021
Figure 2. Forest plots showing the survival outcomes of patient subgroups.
(A) Progression-free survival, (B) overall survival.
Adj, adjusted; CA19-9, carbohydrate antigen 19-9; CI, confidence interval; ECOG, European Eastern Oncology Group; FOLFIRINOX, fluorouracil, leucovorin, irinotecan,
and oxaliplatin; GEM, gemcitabine; HR, hazard ratio; nal-IRI/FL, liposomal irinotecan plus fluorouracil/leucovorin; NLR, neutrophil-lymphocyte ratio; No, number; OS,
overall survival; PFS, progression-free survival.
H. S. Park et al. ESMO OpenFOLFIRINOX has been investigated as second-line therapy
after failure of gemcitabine-based therapy because of its
proven clinical benefit as a first-line treatment.11 Prior
single-arm studies have reported median PFS and OS of 3-6
and 9-10 months, respectively.13,14,19 This could be regar-






No. % No. %
Hematologic
Neutropenia 36 35 128 47.2 0.033
Febrile neutropenia 7 6.8 28 10.3 0.294
Thrombocytopenia 2 1.9 11 4.1 0.528
Anemia 8 7.8 32 11.8 0.259
Non-hematologic
Fatigue 9 8.7 15 5.5 0.259
Mucositis 1 1.0 4 1.5 1.000
Nausea 7 6.8 26 9.6 0.394
Vomiting 6 5.8 16 5.9 0.977
Diarrhea 2 1.9 4 1.5 0.669
Peripheral neuropathy 1 1.0 16 5.9 0.049
AST/ALT elevation 2 1.9 9 3.3 0.734
ALT, alanine aminotransferase; AST, aspartate aminotransferase; FOLFIRINOX, fluo-
rouracil, leucovorin, irinotecan, and oxaliplatin; nal-IRI, liposomal irinotecan; No,
number.
Volume 6 - Issue 2 - 2021better survival outcomes than from historical data on 5-FU-
based monotherapy or 5-FU-oxaliplatin/conventional irino-
tecan doublets.5-9 The median PFS and OS results found in
this study are in line with previous studies.13,14,19 Reduced
doses of FOLFIRINOX were administered to 78.5% of pa-
tients that were included in our retrospective analysis.
However, modified version of FOLFIRINOX showed similar
effectiveness with improved safety profiles when compared
with the original FOLFIRINOX dose reported in previous
studies.20-23 This dose modification does not exclude the
possibility of reduced effectiveness outcomes compared
with the original FOLFIRINOX study; however, 93.4% of
patients were administered with a dose intensity 70% of
the original dose, which has been suggested as the cut-off
for preserving effectiveness in a prior retrospective study.23
Multiple chemotherapeutic regimens, including nal-IRI/
FL, FOLFIRINOX, 5-FU-oxaliplatin doublets (OFF, FOLFOX or
XELOX) or 5-FU-based monotherapy (FL, capecitabine or
S-1), are listed in guidelines as appropriate therapies after
progression following gemcitabine-based therapy24; there-
fore, determining the optimal sequence of chemotherapy
remains challenging in the daily management of medically
fit patients with MPC. This is primarily due to the lack of
randomized trials comparing combination chemotherapy
regimens. To date, no data has been published comparinghttps://doi.org/10.1016/j.esmoop.2021.100049 5
ESMO Open H. S. Park et al.the clinical outcomes between second-line treatment with
nal-IRI/FL and FOLFIRINOX.
This multicenter retrospective analysis found no signifi-
cant difference in terms of objective response rate, PFS, and
OS between second-line nal-IRI/FL and FOLFIRINOX after
progression following first-line gemcitabine-based therapy.
Effectiveness outcomes were numerically better with FOL-
FIRINOX than nal-IRI plus FL/LV; however, this did not reach
significance in univariate and multivariate analyses. Safety
profiles were acceptable and consistent with prior studies
using both regimens. Neutropenia and peripheral neurop-
athy were more common in FOLFIRINOX when compared
with nal-IRI/FL, despite reduced starting doses in most pa-
tients. Our results should be cautiously interpreted because
of potential biases; chemotherapy selection was carried out
by attending physicians in a daily practice setting and this
decision is typically dependent on the patient’s age, per-
formance status, co-morbidities, effectiveness/toxicity pro-
files on prior gemcitabine, and the physicians’ own clinical
experiences with second-line chemotherapy regimens.
Interestingly, our study found that age may be a signifi-
cant factor when choosing between nal-IRI/FL and FOLFIR-
INOX as the second-line treatment. Patients treated with
FOLFIRINOX showed better OS if <70 years old, while pa-
tients treated with nal-IRI/FL showed better PFS and OS if
70 years old. These results were obtained from subgroup
analysis; therefore, further adjustments of other prognostic
factors could not be carried out. This suggests cautious
interpretation is required. Further investigation should be
carried out to define the indicators that should be used to
determine the most appropriate second-line chemotherapy
for patients who show progression following gemcitabine-
based chemotherapy.
This study has several limitations. Primarily, this is a
retrospective study. Potential prognostic factors, such as
age, prior gemcitabine-based regimen, dose modification at
initial cycle, and recurrence within six months after the
completion of adjuvant gemcitabine-based therapy in pa-
tients with prior surgery were imbalanced between groups.
Differences in the first-line gemcitabine-based regimens
might be attributed to the different approval time points of
FOLFIRINOX (2013), nab-paclitaxel (2016), and nal-IRI (2017)
during the study period (since 2015). All our analyses were
carried out by adjusting the potential impact of these fac-
tors; however, the interpretation of our study should be at
the level of hypothesis-generation. Finally, adverse events
might be underestimated considering the retrospective
nature of study design.
Conclusion
Both nal-IRI/FL and FOLFIRINOX showed clinically mean-
ingful effectiveness outcomes as the second-line therapy
after progression following gemcitabine-based therapy.
Safety profiles with these chemotherapy regimens were
well manageable and in line with previous studies. Inter-
estingly, age (cut-off, 70 years) interacted with these
chemotherapy regimens to show differential outcome
measures.6 https://doi.org/10.1016/j.esmoop.2021.100049FUNDING
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